GeneDx Holdings

WGSPre-clinical

GeneDx Holdings Corp., operating as GeneDx, is a commercial-stage genomic diagnostics company that emerged from the combination of GeneDx and Sema4. The company's mission is to expand the use of genomic and clinical data to improve the diagnosis and management of disease globally. It leverages one of the world's largest clinical genomics databases and advanced AI/ML tools to enhance test interpretation and accelerate diagnostic yields. GeneDx is publicly traded on the Nasdaq under the ticker WGS and is strategically positioned to capitalize on the growing adoption of genetic testing in mainstream medicine.

Market Cap

$2.0B

Employees

500-1000

Focus

Biotech

WGS · Stock Price

USD 69.8428.50 (-28.98%)

Historical price data

AI Company Overview

Technology Platform

Leverages a proprietary database of over 2 million clinical genomes/exomes and AI/ML tools (XomeAI) to enhance the interpretation of genetic variants and improve diagnostic yield for complex conditions.

Funding History

Total raised: $225M

PIPE$150MCasdin CapitalJan 15, 2022

Series A$75MCasdin CapitalOct 15, 2020

Opportunities

Significant growth opportunities exist in penetrating the large, underserved rare disease diagnostic market, expanding internationally, and monetizing its unique genomic database through partnerships with biopharma companies for drug discovery and development.

Risk Factors

Key risks include dependence on uncertain insurance reimbursement, intense competition from larger diagnostic labs, potential regulatory changes for lab-developed tests (LDTs), and the ongoing challenge of achieving profitability while investing in growth.

Competitive Landscape

GeneDx competes with large diagnostic labs (Labcorp, Quest), specialized genetic testing firms (Myriad, Fulgent), and academic centers. Its primary differentiation is its massive clinical genomics database and AI-powered interpretation tools, which are particularly valuable for solving complex rare disease cases.

Publications